Sanofi
Latest Stories
new_eczema_drug_22885.jpg
This image provided by Sanofi shows a box containing two single-dose pre-filled syringes of the drug Dupixent. On Tuesday, March 28, 2017, the Food and Drug Administration approved Dupixent for moderate or severe eczema, which causes red, fiercely itchy rashes on the face, arms and legs. (Rodrigo Cid/Sanofi via AP)
0070b53d38020a054b0f6a706700a06a.jpg
Sanofi CEO Christopher A. Viehbacher poses for photographers as he arrives for its annual results in Paris, Thursday, Feb. 6, 2014. The French drug maker said Thursday its earnings soared in the fourth quarter as lower restructuring costs offset a hefty charge related to one of its key multiple sclerosis treatments. (AP Photo/Michel Euler)
ab45c8f5380a0a054b0f6a7067007a17.jpg
Sanofi CEO Christopher A. Viehbacher, left, and President of Sanofi's Global Research and Development, Dr. Elias Zerhouni pose for photographers as they arrive for Sanofi's annual results in Paris, Thursday, Feb. 6, 2014. The French drug maker said Thursday its earnings soared in the fourth quarter as lower restructuring costs offset a hefty charge related to one of its key multiple sclerosis treatments. (AP Photo/Michel Euler)
